dc.creatorVinuesa, María Angeles
dc.creatorPomilio, Carlos Javier
dc.creatorGregosa Merlino, Amal Patricio
dc.creatorBentivegna, Melisa Inés María
dc.creatorPresa, Jessica Lorena
dc.creatorBellotto, Melina
dc.creatorSaravia, Flavia Eugenia
dc.creatorBeauquis, Juan
dc.date.accessioned2021-07-30T00:21:20Z
dc.date.accessioned2022-10-15T04:45:07Z
dc.date.available2021-07-30T00:21:20Z
dc.date.available2022-10-15T04:45:07Z
dc.date.created2021-07-30T00:21:20Z
dc.date.issued2021-04
dc.identifierVinuesa, María Angeles; Pomilio, Carlos Javier; Gregosa Merlino, Amal Patricio; Bentivegna, Melisa Inés María; Presa, Jessica Lorena; et al.; Inflammation and insulin resistance as risk factors and potential therapeutic targets for Alzheimer’s disease; Frontiers Media S.A.; Frontiers in Neuroscience; 15; 4-2021; 1-25
dc.identifier1662-453X
dc.identifierhttp://hdl.handle.net/11336/137405
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4346359
dc.description.abstractOvernutrition and modern diets containing high proportions of saturated fat are among the major factors contributing to a low-grade state of inflammation, hyperglycemia and dyslipidemia. In the last decades, the global rise of type 2 diabetes and obesity prevalence has elicited a great interest in understanding how changes in metabolic function lead to an increased risk for premature brain aging and the development of neurodegenerative disorders such as Alzheimer?s disease (AD). Cognitive impairment and decreased neurogenic capacity could be a consequence of metabolic disturbances. In these scenarios, the interplay between inflammation and insulin resistance could represent a potential therapeutic target to prevent or ameliorate neurodegeneration and cognitive impairment. The present review aims to provide an update on the impact of metabolic stress pathways on AD with a focus on inflammation and insulin resistance as risk factors and therapeutic targets.
dc.languageeng
dc.publisherFrontiers Media S.A.
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fnins.2021.653651/full
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fnins.2021.653651
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectALZHEIMER’S DISEASE
dc.subjectCOGNITIVE IMPAIRMENT
dc.subjectINFLAMMATION
dc.subjectINSULIN RESISTANCE
dc.subjectMETABOLIC DISORDERS
dc.subjectTHERAPIES
dc.titleInflammation and insulin resistance as risk factors and potential therapeutic targets for Alzheimer’s disease
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución